UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
When will regulator visit Kolon TissueGene for inspection?
The Ministry of Food and Drug Safety is likely to decide in mid-May on when...
by Lee Hye-seon
|
2019-05-02 14:09
라인
Civic group files complaint against Kolon, regulator
A non-government consumer group has complained with the prosecution against...
by Jeong Sae-im
|
2019-04-30 14:59
라인
FDA OKs Celltrion’s antibiotics generic
Celltrion said that the U.S. Food and Drug Administration has approved Line...
by Lee Han-soo
|
2019-04-30 11:22
라인
Huons, Genexine to cooperate on biopharmaceuticals
Huons and Genexine have agreed to collaborate on developing new biopharmace...
by Lee Han-soo
|
2019-04-29 15:10
라인
Techniques for biobetters get ever more advanced
Korea’s biotech industry is stepping up efforts to develop biobetters -- up...
by Jeong Sae-im
|
2019-04-29 11:48
라인
Prosecutors seek arrest warrant of Samsung Bioepis executives
The Seoul Central District Prosecutors Office are seeking an arrest warrant...
by Lee Han-soo
|
2019-04-26 17:19
라인
FDA OKs Samsung Bioepis’ Etanercept biosimilar
Samsung Bioepis has received sales approval for Eticovo (Original: Enbrel),...
by Lee Han-soo
|
2019-04-26 14:22
라인
Foreign patients to join class-action suit against Kolon for Invossa
Foreign osteoarthritis patients expressed fury over the mislabeling of ingr...
by Jeong Sae-im
|
2019-04-25 15:39
라인
Samsung Bioepis’ biosimilar sales in EU topped $170 million in Q1
Samsung Bioepis’ biosimilar sales in European Union surpassed $170 million ...
by Lee Han-soo
|
2019-04-25 14:07
라인
Samsung Biologics logs ₩23.4 billion operating loss in Q1
Samsung Biologics said it posted a 23.4 billion won ($20.2 million) operati...
by Jeong Sae-im
|
2019-04-25 12:08
라인
OECD guideline OKs Korean-developed eye irritation test
Eye irritation test developed in Korea has won the approval as the test gui...
by Lee Hye-seon
|
2019-04-22 15:33
라인
Gene therapies’ potentials, challenges explained
Can Korea lead the global market of innovative gene therapies?Healthcare ex...
by Jeong Sae-im
|
2019-04-22 11:46
라인
Why is TissueGene CEO silent about Invossa mislabeling?
Noh Moon-jong, CEO of Kolon TissueGene, is the key person to clarify why In...
by Jeong Sae-im
|
2019-04-19 14:37
라인
‘How Korean pharma companies can succeed in US’
With most Korean pharmaceutical and biosimilar companies aiming to launch t...
by Lee Han-soo
|
2019-04-18 14:41
라인
Kolon desperate to keep Invossa license amid suspicion of data fabrication
Kolon Life Science might get its sales license of Invossa-K revoked, as the...
by Lee Hye-seon
|
2019-04-18 11:16
라인
Patients to file class-action suit against Kolon over Invossa
Local patients who got Invossa-K injection for arthritis treatment will pur...
by Jeong Sae-im
|
2019-04-17 14:58
라인
‘Invossa lacked clinical evidence to be commercialized’
Kolon Life Science’s gene therapy Invossa-K for arthritis treatment had ina...
by Jeong Sae-im
|
2019-04-17 12:45
라인
BIO KOREA 2019 aims to lead open innovation
BIO KOREA 2019 opened for a three-day run at COEX, southern Seoul, Wednesda...
by Lee Han-soo
|
2019-04-17 12:42
라인
Celltrion unveils P2 trial results for influenza antibody therapy
Celltrion has presented the phase 2 clinical trial results for CT-P27, a co...
by Lee Han-soo
|
2019-04-16 16:16
라인
‘Kolon might have fabricated data to get Invossa approval’
The regulator raised suspicion that Kolon Life Science might have tampered ...
by Jeong Sae-im
|
2019-04-16 11:07
-
이전
11
12
13
14
15
16
17
18
19
20
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top